7-Minute Injection To Treat Lung Cancer Comes To India

Roche Pharma India announced the launch of Tecentriq® (atezolizumab) SC in India — the country’s first subcutaneous (under-the-skin) immunotherapy for lung cancer that can be administered in approximately 7 minutes, compared to conventional IV infusions that can take hours. By reducing treatment administration time to approximately 7 minutes, Tecentriq SC is a breakthrough innovation that has the potential to dramatically improve the cancer treatment experience of patients — reducing treatment time by approx. 80%, lowering indirect treatment costs, minimising the need to travel long distances, and enabling and caregivers spend less time in hospitals